154 related articles for article (PubMed ID: 25875794)
1. Prognostic value of altered N-glycosylation of circulating glycoproteins in patients with unresectable pancreatic cancer treated with gemcitabine.
Miyahara K; Nouso K; Morimoto Y; Kinugasa H; Kato H; Yamamoto N; Tsutsumi K; Kuwaki K; Onishi H; Ikeda F; Nakamura S; Shiraha H; Takaki A; Nakahara T; Miura Y; Asada H; Amano M; Nishimura S; Yamamoto K
Pancreas; 2015 May; 44(4):551-6. PubMed ID: 25875794
[TBL] [Abstract][Full Text] [Related]
2. Identification of laminin γ2 as a prognostic and predictive biomarker for determining response to gemcitabine-based therapy in pancreatic ductal adenocarcinoma.
Okada Y; Nishiwada S; Yamamura K; Sho M; Baba H; Takayama T; Goel A
Eur J Cancer; 2021 Mar; 146():125-134. PubMed ID: 33607476
[TBL] [Abstract][Full Text] [Related]
3. IL17RB expression might predict prognosis and benefit from gemcitabine in patients with resectable pancreatic cancer.
Song Y; Ji B; Jiang CX; Chen ZM; Yao NH; Mukaida N; Huang H
Pathol Res Pract; 2019 Dec; 215(12):152650. PubMed ID: 31585811
[TBL] [Abstract][Full Text] [Related]
4. Serum CA19-9 alterations during preoperative gemcitabine-based chemoradiation therapy for resectable invasive ductal carcinoma of the pancreas as an indicator for therapeutic selection and survival.
Takahashi H; Ohigashi H; Ishikawa O; Eguchi H; Gotoh K; Yamada T; Nakaizumi A; Uehara H; Tomita Y; Nishiyama K; Yano M
Ann Surg; 2010 Mar; 251(3):461-9. PubMed ID: 20134315
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia inducible BHLHB2 is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma.
Wang W; Reiser-Erkan C; Michalski CW; Raggi MC; Quan L; Yupei Z; Friess H; Erkan M; Kleeff J
Biochem Biophys Res Commun; 2010 Oct; 401(3):422-8. PubMed ID: 20863812
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors and prognostic index for chemonaïve and gemcitabine-refractory patients with advanced pancreatic cancer.
Maréchal R; Demols A; Gay F; De Maertelaere V; Arvanitaki M; Hendlisz A; Van Laethem JL
Oncology; 2007; 73(1-2):41-51. PubMed ID: 18334830
[TBL] [Abstract][Full Text] [Related]
7. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
[TBL] [Abstract][Full Text] [Related]
8. Survival prediction for pancreatic cancer patients receiving gemcitabine treatment.
Matsubara J; Ono M; Honda K; Negishi A; Ueno H; Okusaka T; Furuse J; Furuta K; Sugiyama E; Saito Y; Kaniwa N; Sawada J; Shoji A; Sakuma T; Chiba T; Saijo N; Hirohashi S; Yamada T
Mol Cell Proteomics; 2010 Apr; 9(4):695-704. PubMed ID: 20061307
[TBL] [Abstract][Full Text] [Related]
9. Early decrement of serum carbohydrate antigen 19-9 predicts favorable outcome in advanced pancreatic cancer.
Chung KH; Ryu JK; Lee BS; Jang DK; Lee SH; Kim YT
J Gastroenterol Hepatol; 2016 Feb; 31(2):506-12. PubMed ID: 26250642
[TBL] [Abstract][Full Text] [Related]
10. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma.
Maréchal R; Bachet JB; Mackey JR; Dalban C; Demetter P; Graham K; Couvelard A; Svrcek M; Bardier-Dupas A; Hammel P; Sauvanet A; Louvet C; Paye F; Rougier P; Penna C; André T; Dumontet C; Cass CE; Jordheim LP; Matera EL; Closset J; Salmon I; Devière J; Emile JF; Van Laethem JL
Gastroenterology; 2012 Sep; 143(3):664-674.e6. PubMed ID: 22705007
[TBL] [Abstract][Full Text] [Related]
11. Notch1 contributes to chemoresistance to gemcitabine and serves as an unfavorable prognostic indicator in pancreatic cancer.
Du X; Zhao YP; Zhang TP; Zhou L; Chen G; Cui QC; Shi J; Wang TX; You L; Shu H
World J Surg; 2013 Jul; 37(7):1688-94. PubMed ID: 23568245
[TBL] [Abstract][Full Text] [Related]
12. A prognostic model to predict clinical outcomes with first-line gemcitabine-based chemotherapy in advanced pancreatic cancer.
Yi JH; Lee J; Park SH; Lee KT; Lee JK; Lee KH; Choi DW; Choi SH; Heo JS; Lim DH; Park YS; Lim HY; Kang WK; Park K; Park JO
Oncology; 2011; 80(3-4):175-80. PubMed ID: 21701231
[TBL] [Abstract][Full Text] [Related]
13. Serum N-Glycome analysis reveals pancreatic cancer disease signatures.
Vreeker GCM; Hanna-Sawires RG; Mohammed Y; Bladergroen MR; Nicolardi S; Dotz V; Nouta J; Bonsing BA; Mesker WE; van der Burgt YEM; Wuhrer M; Tollenaar RAEM
Cancer Med; 2020 Nov; 9(22):8519-8529. PubMed ID: 32898301
[TBL] [Abstract][Full Text] [Related]
14. CA 19-9 response as an early indicator of the effectiveness of gemcitabine in patients with advanced pancreatic cancer.
Nakai Y; Kawabe T; Isayama H; Sasaki T; Yagioka H; Yashima Y; Kogure H; Arizumi T; Togawa O; Ito Y; Matsubara S; Hirano K; Sasahira N; Tsujino T; Tada M; Omata M
Oncology; 2008; 75(1-2):120-6. PubMed ID: 18784438
[TBL] [Abstract][Full Text] [Related]
15. The absence of class III β-tubulin is predictive of a favorable response to nab-paclitaxel and gemcitabine in patients with unresectable pancreatic ductal adenocarcinoma.
Kato A; Naiki-Ito A; Naitoh I; Hayashi K; Nakazawa T; Shimizu S; Nishi Y; Okumura F; Inoue T; Takada H; Kondo H; Yoshida M; Takahashi S; Joh T
Hum Pathol; 2018 Apr; 74():92-98. PubMed ID: 29339176
[TBL] [Abstract][Full Text] [Related]
16. Unresectable pancreatic ductal adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting outcomes of patients treated with chemotherapy.
Cheng SH; Cheng YJ; Jin ZY; Xue HD
Eur J Radiol; 2019 Apr; 113():188-197. PubMed ID: 30927946
[TBL] [Abstract][Full Text] [Related]
17. High expression of CX3CL1/CX3CR1 axis predicts a poor prognosis of pancreatic ductal adenocarcinoma.
Xu X; Wang Y; Chen J; Ma H; Shao Z; Chen H; Jin G
J Gastrointest Surg; 2012 Aug; 16(8):1493-8. PubMed ID: 22639377
[TBL] [Abstract][Full Text] [Related]
18. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial.
Hess V; Glimelius B; Grawe P; Dietrich D; Bodoky G; Ruhstaller T; Bajetta E; Saletti P; Figer A; Scheithauer W; Herrmann R
Lancet Oncol; 2008 Feb; 9(2):132-8. PubMed ID: 18249033
[TBL] [Abstract][Full Text] [Related]
19. [Modern possibilities of chemotherapy in patients with ductal pancreatic adenocarcinoma].
Kopchak VM; Kopchak KV; Romaniv IaV
Klin Khir; 2006 Feb; (2):23-5. PubMed ID: 16826811
[TBL] [Abstract][Full Text] [Related]
20. Circulating regulatory T cell subsets predict overall survival of patients with unresectable pancreatic cancer.
Liu C; Cheng H; Luo G; Lu Y; Jin K; Guo M; Ni Q; Yu X
Int J Oncol; 2017 Aug; 51(2):686-694. PubMed ID: 28714519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
